VYBRIQUE Drug Patent Profile
✉ Email this page to a colleague
When do Vybrique patents expire, and when can generic versions of Vybrique launch?
Vybrique is a drug marketed by Ibsa and is included in one NDA. There is one patent protecting this drug.
The generic ingredient in VYBRIQUE is sildenafil citrate. There is one drug master file entry for this compound. Sixty-five suppliers are listed for this compound. Additional details are available on the sildenafil citrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vybrique
A generic version of VYBRIQUE was approved as sildenafil citrate by CHARTWELL RX on November 6th, 2012.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for VYBRIQUE?
- What are the global sales for VYBRIQUE?
- What is Average Wholesale Price for VYBRIQUE?
Summary for VYBRIQUE
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| What excipients (inactive ingredients) are in VYBRIQUE? | VYBRIQUE excipients list |
| DailyMed Link: | VYBRIQUE at DailyMed |
Pharmacology for VYBRIQUE
| Drug Class | Phosphodiesterase 5 Inhibitor |
| Mechanism of Action | Phosphodiesterase 5 Inhibitors |
US Patents and Regulatory Information for VYBRIQUE
VYBRIQUE is protected by one US patents and one FDA Regulatory Exclusivity.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ibsa | VYBRIQUE | sildenafil citrate | FILM;ORAL | 210858-001 | Dec 16, 2025 | RX | Yes | No | 11,123,287 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Ibsa | VYBRIQUE | sildenafil citrate | FILM;ORAL | 210858-004 | Dec 16, 2025 | RX | Yes | Yes | 11,123,287 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Ibsa | VYBRIQUE | sildenafil citrate | FILM;ORAL | 210858-002 | Dec 16, 2025 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ibsa | VYBRIQUE | sildenafil citrate | FILM;ORAL | 210858-004 | Dec 16, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ibsa | VYBRIQUE | sildenafil citrate | FILM;ORAL | 210858-001 | Dec 16, 2025 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for VYBRIQUE
See the table below for patents covering VYBRIQUE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 2886086 | ⤷ Start Trial | |
| China | 104884041 | ⤷ Start Trial | |
| Denmark | 2900215 | ⤷ Start Trial | |
| European Patent Office | 2900215 | ⤷ Start Trial | |
| Spain | 2640729 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VYBRIQUE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0463756 | SPC/GB99/004 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: SILDENAFIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE CITRATE SALT; REGISTERED: CH 54642 19980622; UK EU/1/98/077/001 19980914; UK EU/1/98/077/002 19980914; UK EU/1/98/077/003 19980914; UK EU/1/98/077/004 19980914; UK EU/1/98/077/005 19980914; UK EU/1/98/077/006 19980914; UK EU/1/98/077/007 19980914; UK EU/1/98/077/008 19980914; UK EU/1/98/077/009 19980914; UK EU/1/98/077/010 19980914; UK EU/1/98/077/011 19980914; UK EU/1/98/077/012 19980914 |
| 0463756 | 99C0007 | Belgium | ⤷ Start Trial | PRODUCT NAME: SILDENAFIL, NATL REGISTRATION NO/DATE: EU/1/98/077/001 19980914; FIRST REGISTRATION: CH 54642 19980622 |
| 0463756 | C990005 | Netherlands | ⤷ Start Trial | PRODUCT NAME: SILDENAFIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT, IN HET BIJZONDER SILDENAFIL CITRAAT; NATL REGISTRATION NO/DATE: EU/1/98/077/001-012 19980914; FIRST REGISTRATION: CH 54642 19980622 |
| 0463756 | 5/1999 | Austria | ⤷ Start Trial | PRODUCT NAME: ''SILDENAFIL'' UND DESSEN PHARMAZEUTISCH ANNEHMBAREN SALZE, EINSCHLIESSLICH DES CITRATS; NAT. REGISTRATION NO/DATE: EU/1/98/077/001 - EU/1/98/077/012 19980914; FIRST REGISTRATION: LI 54642 01-54642 03 19980622 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch